EPITHET: Positive Result After Reanalysis Using Baseline Diffusion-Weighted Imaging/Perfusion-Weighted Imaging Co-Registration.
Standard
EPITHET: Positive Result After Reanalysis Using Baseline Diffusion-Weighted Imaging/Perfusion-Weighted Imaging Co-Registration. / Nagakane, Yoshinari; Christensen, Soren; Brekenfeld, Caspar; Ma, Henry; Churilov, Leonid; Parsons, Mark W; Levi, Christopher R; Butcher, Kenneth S; Peeters, Andre; Barber, P Alan; Bladin, Christopher F; Silva, De; Deidre, A; Fink, John; Kimber, Thomas E; Schultz, David W; Muir, Keith W; Tress, Brian M; Desmond, Patricia M; Davis, Stephen M; Donnan, Geoffrey A; Investigators, EPITHET.
In: STROKE, Vol. 42, No. 1, 1, 2011, p. 59-64.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - EPITHET: Positive Result After Reanalysis Using Baseline Diffusion-Weighted Imaging/Perfusion-Weighted Imaging Co-Registration.
AU - Nagakane, Yoshinari
AU - Christensen, Soren
AU - Brekenfeld, Caspar
AU - Ma, Henry
AU - Churilov, Leonid
AU - Parsons, Mark W
AU - Levi, Christopher R
AU - Butcher, Kenneth S
AU - Peeters, Andre
AU - Barber, P Alan
AU - Bladin, Christopher F
AU - Silva, De
AU - Deidre, A
AU - Fink, John
AU - Kimber, Thomas E
AU - Schultz, David W
AU - Muir, Keith W
AU - Tress, Brian M
AU - Desmond, Patricia M
AU - Davis, Stephen M
AU - Donnan, Geoffrey A
AU - Investigators, EPITHET
PY - 2011
Y1 - 2011
N2 - the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a prospective, randomized, double-blinded, placebo-controlled, phase II trial of alteplase between 3 and 6 hours after stroke onset. The primary outcome of infarct growth attenuation on MRI with alteplase in mismatch patients was negative when mismatch volumes were assessed volumetrically, without coregistration, which underestimates mismatch volumes. We hypothesized that assessing the extent of mismatch by coregistration of perfusion and diffusion MRI maps may more accurately allow the effects of alteplase vs placebo to be evaluated.
AB - the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a prospective, randomized, double-blinded, placebo-controlled, phase II trial of alteplase between 3 and 6 hours after stroke onset. The primary outcome of infarct growth attenuation on MRI with alteplase in mismatch patients was negative when mismatch volumes were assessed volumetrically, without coregistration, which underestimates mismatch volumes. We hypothesized that assessing the extent of mismatch by coregistration of perfusion and diffusion MRI maps may more accurately allow the effects of alteplase vs placebo to be evaluated.
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Time Factors
KW - Diffusion Magnetic Resonance Imaging
KW - Brain Infarction/drug therapy/metabolism/radiography
KW - Fibrinolytic Agents/administration & dosage
KW - Tissue Plasminogen Activator/administration & dosage
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Time Factors
KW - Diffusion Magnetic Resonance Imaging
KW - Brain Infarction/drug therapy/metabolism/radiography
KW - Fibrinolytic Agents/administration & dosage
KW - Tissue Plasminogen Activator/administration & dosage
M3 - SCORING: Journal article
VL - 42
SP - 59
EP - 64
JO - STROKE
JF - STROKE
SN - 0039-2499
IS - 1
M1 - 1
ER -